BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

Sunday was International Women’s Day. I looked back at a column I wrote in 2018 wondering how much of it was still relevant. Can something as fundamental as the situation for women in our industry...
BioCentury | Feb 22, 2020
Product Development

FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

FDA's approval of Vyepti eptinezumab-jjmr from Lundbeck is the first for an IV-delivered CGRP inhibitor for migraine prevention, but the therapy will face competition from established subcutaneous drugs in its class. Already on the market...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Sep 24, 2019
Company News

Lundbeck, Alder negotiated ex-U.S. deal before opting for takeout

After soliciting offers from multiple parties to obtain ex-U.S. rights to its migraine treatment, Alder continued to negotiate such a deal with Lundbeck -- while also working out an outright acquisition offer the biotech would...
BC Extra | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

Japanese approvals include Tecentriq for TNBC  Japan’s Ministry of Health, Labour and Welfare expanded the label of Tecentriq atezolizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) to include PD-L1-positive triple-negative breast cancer. MHLW also approved serotonin...
BC Extra | Sep 16, 2019
Company News

Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs...
Items per page:
1 - 10 of 1088
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

Sunday was International Women’s Day. I looked back at a column I wrote in 2018 wondering how much of it was still relevant. Can something as fundamental as the situation for women in our industry...
BioCentury | Feb 22, 2020
Product Development

FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

FDA's approval of Vyepti eptinezumab-jjmr from Lundbeck is the first for an IV-delivered CGRP inhibitor for migraine prevention, but the therapy will face competition from established subcutaneous drugs in its class. Already on the market...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Sep 24, 2019
Company News

Lundbeck, Alder negotiated ex-U.S. deal before opting for takeout

After soliciting offers from multiple parties to obtain ex-U.S. rights to its migraine treatment, Alder continued to negotiate such a deal with Lundbeck -- while also working out an outright acquisition offer the biotech would...
BC Extra | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

Japanese approvals include Tecentriq for TNBC  Japan’s Ministry of Health, Labour and Welfare expanded the label of Tecentriq atezolizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) to include PD-L1-positive triple-negative breast cancer. MHLW also approved serotonin...
BC Extra | Sep 16, 2019
Company News

Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs...
Items per page:
1 - 10 of 1088